This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (4) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ezewuzie, N. Articles by Taylor, D. Search for Related Content PubMed PubMed Citation Articles by Ezewuzie, N. Articles by Taylor, D. Social Bookmarking                         What's this?

Establishing a dose-response relationship for oral risperidone in relapsed schizophrenia

Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK

David Taylor, MSc PhD MRPharmS

Maudsley Hospital, Denmark Hill, London SE5 8AZ, UK, david.taylor{at}slam.nhs.uk

For many antipsychotics, dose-response relationships remain poorly understood. High dose treatment remains commonplace. We aimed to establish the dose-response relationship for oral risperidone in relapsed schizophrenia. We searched the known medical literature for fixed-dose studies of oral risperidone in this patient group. Data recovered were used to construct graphs of dose versus response. Eighteen reports evaluating the efficacy of oral risperidone were retrieved. Three studies used fixed doses of oral risperidone for eight weeks in relapsed schizophrenia. The data from these studies were included. Graphs plotted using these data strongly suggest that doses of around 4mg daily are optimal. A dose of 2mg daily consistently produced a lower level of efficacy. Doses of 6mg or greater produced no additional benefit and doses tend to be less efficacious at 10mg daily and above. Frequency of extrapyramidal adverse effects increased with dose. The optimal dose of risperidone in relapsed schizophrenia is 4mg daily. Higher doses are unlikely to improve efficacy and may reduce it. Adverse movement disorders become more common.

Key Words: risperidone • schizophrenia • antipsycotic • dose-response

References

• Aubree J C, Lader M H (1980) High and very high dosage antipsychotics: a critical review . J Clin Psychiatry 41(10): 341-350 [Web of Science][Medline] [Order article via Infotrieve]
• Baldessarini R J, Cohen B M, Teicher M H (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses . Arch Gen Psychiatry 45: 79 [Abstract/Free Full Text]
• Bollini P, Pampallona S, Orza M J, Adams M E, Chalmers T C (1994) Antipsychotic drugs: Is more worse? A meta-analysis of the published randomized control trials . Psychological Medicine 24: 307-316 [Web of Science][Medline] [Order article via Infotrieve]
• Borison R L, Pathiraja A P, Diamond B I, Meibach R C (1992) Risperidone: clinical safety and efficacy in schizophrenia . Psychopharmacol Bull 28(2): 213-218 [Web of Science][Medline] [Order article via Infotrieve]
• Chouinard G, Jones B, Remington G, Bloom D, Addington D, MacEwan G W, Labelle A, Beauclair L, Arnott W (1993) A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients . J Clin Psychopharmacol 13(1): 25-40 [Web of Science][Medline] [Order article via Infotrieve]
• Claus A, Bollen C A, De Cuyper H, Eneman M, Malfroid M, Peuskens J, Heylen S (1992) Risperidone versus haloperidol in the treatment of chronic schizophrenic inpatients: a multicentre double-blind comparative study . Acta Psychiatr Scand 85: 295-305 [Web of Science][Medline] [Order article via Infotrieve]
• Davis J M, Chen N (2004) Dose response and dose equivalence of antipsychotics . J Clin Psychopharmacol 24(2): 192-208 [CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Davis J M, Chen N, Glick I D (2003) A meta-analysis of the efficacy of second-generation antipsychotics . Arch Gen Psychiatry 60: 553-564 [Abstract/Free Full Text]
• Farde L, Nyberg S, Oxenstierna G, Nakashima Y, Halldin C (1995) Positron emission tomography studies on D2 and 5-HT2 receptor binding in risperidone-treated schizophrenic patients . J Clin Psychopharmacol 15(1 Suppl 1): 19S-23S [Medline] [Order article via Infotrieve]
• Gilbody S M, Bagnall A M, Duggan L, Tuunainen A. (2000) Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review). In The Cochrane Library, Issue 2, 2004. John Wiley & Sons, Ltd, Chichester, UK
• Glick I D, Lemmens P, Vester-Blokland E (2001) Treatment of the symptoms of schizophrenia: a combined analysis of double-blind studies comparing risperidone with haloperidol and other antipsychotic agents . Int Clin Psychopharmacol 15(5): 265-274
• Ho B, Miller D, Nopoulos P, Andreasen N C (1999) A comparative effectiveness study of risperidone and olanzapine in the treatment of schizophrenia . J Clin Psychiatry 60(10): 658-663 [Medline] [Order article via Infotrieve]
• Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia . Am J Psychiatry 157(4): 514-520 [Abstract/Free Full Text]
• Kay S R, Fiszbein A, Opler L A (1987) The Positive and Negative Syndrome Scale (PANSS) for Schizophrenia . Schizophr Bull 13: 261-267 [Abstract/Free Full Text]
• Love R C, Conley R R, Kelly D L, Bartko J J (1999) A dose-outcome analysis of risperidone . J Clin Psychiatry 60(11): 771-775 [Medline] [Order article via Infotrieve]
• Luchins D J, Klass D, Hanrahan P, Malan R, Harris J (1998) Alteration in the recommended dosing schedule for risperidone . Am J Psychiatry 155(3): 365-366 [Abstract/Free Full Text]
• Marder S R, Davis J M, Chouinard G (1997) The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials . J Clin Psychiatry 58(12): 538-546 [Web of Science][Medline] [Order article via Infotrieve]
• Marder S R, Meibach R C (1994) Risperidone in the treatment of schizophrenia . Am J Psychiatry 151(6): 825-835 [Abstract/Free Full Text]
• McEvoy J P (1994) Efficacy of risperidone on positive features of schizophrenia . J Clin Psychiatry 55(5, Suppl): 18-21
• Merlo M C G, Hofer H, Gekle W, Berger G, Ventura J, Panhuber I, Latour G, Marder S R (2002) Risperidone 2mg/day vs. 4mg/day, in first-episode acutely psychotic patients: treatment efficacy and effects on fine motor functioning . J Clin Psychiatry 63(10): 885-891 [Medline] [Order article via Infotrieve]
• Nair N P V, the Risperidone Study Group (1998) Therapeutic equivalence of risperidone given once daily and twice daily in patients with schizophrenia . J Clin Psychopharmacol 18(2): 103-110 [CrossRef][Medline] [Order article via Infotrieve]
• Nyberg S, Eriksson B, Oxenstierna G, Halldin C, Farde L (1999) Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients . Am J Psychiatry 156(6): 869-875 [Abstract/Free Full Text]
• Peuskens J and the Risperidone Study Group (1995) Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-center, double-blind, parallel-group study versus haloperidol . Br J Psychiatry 166: 712-726 [Abstract/Free Full Text]
• Potkin S G, Gutierrez R (1997) Safety and efficacy of once daily risperidone in the treatment of schizophrenia . Presented at the 6th World Congress of Biological Psychiatry, Nice, France, 22-27 June 1997
• Suzuki T, Uchida H, Tanaka K F, Tomita M, Tsunoda K, Nomura K, Takano H, Tanabe A, Watanabe K, Yagi G, Kashima H (2003) Reducing the dose of antipsychotic medications for those who had been treated with high-dose antipsychotic polypharmacy: an open study of dose reduction for chronic schizophrenia . Int Clin Psychopharmacol 18(6): 323-329 [CrossRef][Medline] [Order article via Infotrieve]
• Williams R (2001) Optimal dosing with risperidone: updated recommendations . J Clin Psychiatry 62(4): 282-289 [Medline] [Order article via Infotrieve]

This version was published on January 1, 2006

Journal of Psychopharmacology, Vol. 20, No. 1, 86-90 (2006)
DOI: 10.1177/0269881105057001


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Web of Science (4) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Ezewuzie, N. Articles by Taylor, D. Search for Related Content PubMed PubMed Citation Articles by Ezewuzie, N. Articles by Taylor, D. Social Bookmarking                         What's this?